The Medicine
Meets the Moment
A Pipeline of Autoantibody-Driven
Diseases & Blockbuster Opportunities
1
Commercial Approvals
subheading 1
111 – Systemic Lupus Erythematosus (SLE)
112 – Rheumatoid Arthritis (RA)
113 – Myasthenia Gravis (MG)
2
Industrial Approvals
subheading 2
211 – Systemic Lupus Erythematosus (SLE)
212 – Rheumatoid Arthritis (RA)
213 – Myasthenia Gravis (MG)
3
Residential Approvals
subheading 3
311 – Systemic Lupus Erythematosus (SLE)
312 – Rheumatoid Arthritis (RA)
313 – Myasthenia Gravis (MG)
70,000+
Patients Treated Commercially in China
A Pipeline of Autoantibody-Driven
Diseases & Blockbuster Opportunities
Primary Sjögren’s Disease
290,000
Potential Patients in the US Alone
SLE
240,000
Potential Patients in the US Alone
ANCA-AAC
140,000
Potential Patients in the US Alone
Total Addressable Patients
1,000,000
Potential Patients in the US Alone
Last card testing
Final 2%
Potential Patients in the US Alone
1,000,000+
Potential Patients in the US Alone
